Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease by Piedad, John C. P. & Cavanna, Andrea E.
Hindawi Publishing Corporation
Parkinson’s Disease
Volume 2012, Article ID 473769, 8 pages
doi:10.1155/2012/473769
Review Article
DyskinesiasandTreatmentwithPramipexoleinPatients with
Parkinson’s Disease
John C. P. Piedad1,2 andAndreaE.Cavanna1,3
1Michael Trimble Neuropsychiatry Research Group, University of Birmingham and BSMHFT, Birmingham, UK
2Department of Neuropsychiatry and Barberry National Centre for Mental Health, University of Birmingham and BSMHFT,
25 Vincent Drive, Birmingham B15 2FG, UK
3Sobell Department of Motor Neuroscience and Movement Disorders, UCL, Institute of Neurology, London WC1N 3BG, UK
Correspondence should be addressed to Andrea E. Cavanna, a.cavanna@ion.ucl.ac.uk
Received 1 July 2011; Revised 30 October 2011; Accepted 14 November 2011
Academic Editor: Gilberto Fisone
Copyright © 2012 J. C. P. Piedad and A. E. Cavanna. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Dopamineagonistssuchaspramipexole(PPX)haveﬁrstbeenproposedasadjunctivetreatmenttolevodopa(L-DOPA)forpatients
with Parkinson’s disease (PD) and then as a monotherapy alternative to alleviate dyskinesia. Treatment with PPX has overall
been associated with improvement in parkinsonian symptoms. Although the majority of placebo-controlled studies demonstrated
that dyskinesia was more prevalent in the PPX compared to the placebo groups, some studies did not detect any dyskinesia as a
side eﬀect of this medication. PPX was consistently associated with lower risk for developing dyskinesia compared to L-DOPA.
Moreover, the presence of these symptoms in the placebo groups suggests involvement of non-PPX-related factors for developing
dyskinesia. It is suggested that future research should aim at ascertaining whether cotherapy with L-DOPA, PPX dosage, and other
patient characteristics are contributory factors for the development of PPX-related dyskinesia in patients with PD.
1.DyskinesiainParkinson’sDisease
Parkinson’s disease (PD) is a neurodegenerative disease char-
acterised by motor (particularly tremor, rigidity, and brad-
ykinesia)aswellascognitiveandbehaviouralsymptoms.The
pathophysiology of PD has been related to the degeneration
of nigrostriatal dopaminergic pathways [1], and this has
allowed the treatment for PD to be targeted towards
modulating dopamine (DA) neurotransmission (Figure 1).
Levodopa (L-DOPA) has long been the mainstay of PD
treatment although over time patients on L-DOPA develop
motor complications including dyskinesias, which are asso-
ciated with the timing of drug administration. Dyskinesias
are involuntary muscular contractions and include choreic,
dystonic, myoclonic, and tic movements [2]. After 5 and 10
years of L-DOPA therapy, 91% and all of the participants
in a longitudinal cohort (N = 99), respectively, experienced
dyskinesias[3].Anotherstudyalsoidentiﬁedthatcumulative
L-DOPA dosage was signiﬁcantly associated with the devel-
opment of dyskinesia [4].
Given that dyskinesias has been consistently shown to
negatively aﬀect patients’ quality of life [5, 6], there is
considerable debate on how to forestall its onset, including
initial treatment with another class of drugs: the dopamine
receptor agonists (DAAs) [7, 8]. Pramipexole (PPX) belongs
to this drug class and is selective for the D2-like receptor
subfamily, particularly the D3 compared to the D2 and D4
subtypes [9]. Following the observation by Hauser et al.
[4] that treatment with PPX was signiﬁcantly associated
with later onset of dyskinesia, we carried out a systematic
literature review to examine the eﬀects of PPX therapy on
dyskinetic events in patients with PD.
2.LiteratureSearchMethodology
This paper systematically reviews the existing evidence on
the development of dyskinesia during PPX therapy for PD.
We performed a literature search across the databases Med-
line, EMBASE and PsycInfo via the NHS Evidence tool
(http://www.library.nhs.uk). We used the search terms2 Parkinson’s Disease
TYR
L-DOPA
DA
MAO
MAO inhibitors
DA autoreceptor
DA agonists
DAR
DAT
3-MT
COMT
COMT inhibitors
Deaminated
products
Figure 1: Treatment of Parkinson’s disease: anti-Parkinson’s medications modulate key stages of dopaminergic neurotransmission.
Abbreviations: TYR: tyrosine, L-DOPA: L-3, 4-dihydroxyphenylalanine, DA: dopamine, MAO: monoamine oxidase, DAT: DA reuptake
transporter, COMT: catechol-O-methyltransferase, 3-MT: 3-methoxytyramine, DAR: DA receptor. Anti-Parkinson’s drugs are highlighted
in bold. Pointed arrows indicate stimulatory, and closed arrows indicate inhibitory activity.
“Parkinson∗,” “dyskinesi∗,” and “pramipexole”. The Co-
chrane Library was also searched for randomised and
double-blind human trials of PPX in patients with PD. We
limited our search to papers published in English language.
3. Pramipexole-PlaceboComparisons
The majority of the studies on PPX included in this review
were comparisons with placebo only (Table 1). Six out of ten
ofthesestudiesfoundthatdyskinesiainPPX-treatedpatients
was prevalent, at a higher rate than in the placebo group.
The incidence of dyskinesia was 7.0–61.3% and 3.0–40.8%
in the PPX and placebo groups, respectively [10–15]. The
diﬀerencesinratesofdyskinesiawerebetween4.9and20.5%.
Two of these studies had follow-up data. An extension to
the Lieberman et al. [10] protocol by up to 50 months was
carried out, in which both PPX and placebo groups were re-
titrated onto open-label PPX [16]. Out of the sample (N =
306), 61.1% reported dyskinesias, but there were no related
discontinuations. Furthermore, UPDRS IV scores remained
below the baseline values, indicating some improvements in
these symptoms. M¨ oller et al. [13]r e p o r t e da no p e n - l a b e l
extension to their study of up to 57 months follow-up. Out
of their cohort, 34.4% (N = 262) developed dyskinesias.
This led to study discontinuation in 2.3% of participants.
Two studies reported the incidence of dyskinesia to be higher
with the placebo than the PPX groups: 0.6% versus 0.0%
[17] and 6.1% versus 5.6% [18]. However, it should be
noted that the strength of such evidence is weak. One study
[17] was speciﬁcally designed to assess the antiparkinsonian
properties in early PD, rather than the potential dyskinetic
eﬀectsofpramipexole.Theotherone[18]found2dyskinetic
patients in a group of 33 patients treated with placebo and
2 dyskinetic patients in a group of 36 patients treated with
PPX. Of note, a further study failed to identify participants
who experienced dyskinesia with PPX treatment or placebo
[19, 20].
Intermsofneurologicalscalesasameasureofdyskinesia,
Lieberman et al. [10] reported that % change in UPDRS IV
scores was signiﬁcantly (P<. 0001) higher in the PPX group
compared to the placebo group. Changes in the PDS were
not statistically signiﬁcant. These exact patterns in UPDRS
IV and PDS scores were reproduced by Pinter et al. [11]a n d
M¨ oller et al. [13]. In these studies, however, the incidence
of dyskinesia was higher with PPX treatment than placebo.
Wermuth et al. [18] did not ﬁnd signiﬁcant changes in
UPDRS IV or PDS scores. In a cross-over design with PPX
a n dp l a c e b o ,a sw e l la sL - D O P Ai n f u s i o nb e f o r ea n da f t e rt h e
switch-over, Brodsky et al. [32] found that PPX treatment
increased PDS scores to statistically signiﬁcant levels (P =
.05). Furthermore, L-DOPA infusion also increased peak
dyskinesia scores.
4.StudieswithActiveComparators
4.1. Pramipexole Only. There have been two studies com-
paring diﬀerent dosages and other two looking at diﬀerent
preparations of PPX. One of the earliest investigations on
PPX was carried out by the Parkinson Study Group [21],
which compared four diﬀerent dosages of the drug (1.5, 3.0,
4.5, and 6.0mg) against placebo. Another study by the same
group compared diﬀerent low-dose schedules of PPX [21].
Both did not detect any incidence of dyskinesia. Likewise,
comparisons of immediate release (IR) and extended release
(ER) PPX preparations failed to detect any incidence of
dyskinesia symptoms in either treatment or placebo group
[26, 27].
4.2. Pramipexole versus Other Dopamine Agonists. Other
DAAs have been compared with PPX. Two studies reported
a comparison with bromocriptine (BRC), showing that
dyskinesias were found more often with DAAs compared
with placebo. In terms of UPDRS IV and PDS scores, there
were no signiﬁcant changes in one trial [29], whereas, inParkinson’s Disease 3
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the other, % UPDRS IV score changes were signiﬁcantly
lower in the PPX compared to the placebo group [30]. When
comparing PPX and BRC, Guttman et al. [29] found that the
incidence of dyskinesia between these treatment groups was
approximately similar (5% diﬀerence). On the other hand,
dyskinesia was found to be nearly twice as prevalent with
PPX treatment compared to BRC [30].
Two studies compared pergolide (PGL) with PPX. One
of these studies found that dyskinesia was equally prevalent
with PPX and PGL (N = 1) but was not reported in
the placebo group [23]. Another trial by the same group
with a cross-over design found an overall lower incidence
of dyskinesia with PPX treatment than PGL: 33.3% versus
37.5% [25]. Transdermally administered rotigotine (RTG)
was also compared with PPX [31]. The placebo group
had less dyskinesia than the active treatment groups, with
PPX having slightly higher incidence than RTG (3% versus
15% versus 12%). Furthermore, this group reported that
participants in the PPX group had signiﬁcantly more time
in the day “on” without troublesome dyskinesias compared
to placebo (P = .0429), whereas the diﬀerence between PPX
and RTG was not signiﬁcant.
4.3. Pramipexole versus L-DOPA. Only one cohort was in-
volved with a trial comparing PPX and L-DOPA. The ﬁrst
report was the two-year completion of initial treatment with
PPX and L-DOPA, with open-label L-DOPA for emerging
disability [22]. There was a signiﬁcantly lower incidence
of dyskinesia in the PPX compared to the L-DOPA group:
9.9% versus 30.7%, hazard ratio (HR) 0.33 (conﬁdence
interval (CI) 0.18–0.60), P<. 001. Some of the participants
who completed the two-year trial were also enrolled for
a further two-year follow-up study, with the randomised
and blinded protocol maintained [24]. This showed a
similar pattern of the incidence of dyskinesia, which was
signiﬁcantly lower in the PPX (N = 83) compared to
the L-DOPA (N = 100) group: 24.5% versus 54.0%, HR
0.37 (95% CI 0.25–0.56), P<. 001. None of the PPX
cohort withdrew from follow-up due to dyskinesia, whereas
dyskinesia-related discontinuation was found in 2.0% of the
L-DOPA group. Some of the patients in the 2-and 4-year
trials were also recruited to the open-label extension study
with mean follow-up of 6.0 (SD 0.2) years, the majority
of whom were in H-Y stages 2 [35]. Both the initial PPX
(N = 108) and L-DOPA (N = 114) groups showed
overall reductions in the incidence of dyskinesia: 20.4%
and 36.8%, respectively. Despite changes in the incidence of
dyskinesia in the treatment groups compared to the previous
reports of this cohort, L-DOPA treatment was associated
with higher events. Furthermore, disability associated with
dyskinesia in the PPX group was comparably lower than that
in the L-DOPA group, which was at trend-level signiﬁcance
(P = .06).
5. Are There Indicators for the Development of
DyskinesiawithPPX Treatment?
The majority of placebo-controlled studies demonstrated
thatdyskinesiascandevelopduringPPXtreatment.Theinci-
Table 2: Pharmacokinetic proﬁles of selected anti-Parkinson’s
drugs.
APD Half-life (hrs)
PPX 8–12
L-DOPA/carbidopa 1–1.5
RTG 5–7
PGL 7–16
BRC 12–15
Abbreviations: APD: anti-Parkinson’s drug, PPX: pramipexole, L-DOPA:
levodopa, RTG: rotigotine, PGL: pergolide, BRC: bromocriptine.
dence of these events in the placebo groups ranged between
0 and 40.8%, and the diﬀerences compared to the PPX group
ranged between 4.0 and 21.3%. Two studies demonstrated
slightly more dyskinesia in the placebo compared to the PPX
group [17, 18]. These results clearly indicate that there are
non-PPX-related factors contributing to the development of
dyskinesias in PD.
Treatment of L-DOPA has been proposed as an impor-
tantfactorforthedevelopmentofdyskinesiainPD[4].From
the two trials and the long-term follow-up of their cohort
[22, 24, 35], the PSG consistently demonstrated a higher
incidence of dyskinesia associated with L-DOPA therapy.
Furthermore, Brodsky et al. [32] showed that PPX treatment
increased L-DOPA-related dyskinesias and increased the
severity and duration of dyskinesia. They hypothesised that
the observed eﬀects in their study are beyond potential
additive eﬀects, given that DAAs rarely cause dyskinesia. The
2-hour infusion of therapeutic dose L-DOPA (1.0mg/kg/hr)
also produced more dyskinesia compared to subtherapeutic
doses (0.5mg/kg/hr), regardless of PPX treatment. These
ﬁndings suggest that L-DOPA on its own can have some
eﬀect on dyskinesia events during PPX therapy. Although
a study distinguished between L-DOPA and non-L-DOPA-
treated participants, the report about adverse event-related
withdrawals (including dyskinesia) in the L-DOPA group
was not supplemented by information about what propor-
tions were aﬀected [12]. The eﬀects of L-DOPA in other
studies are also less clear because L-DOPA usage is reported
for the whole sample and there is no diﬀerentiation of which
patients were dyskinetic.
The literature also allows limited exploration from clin-
ical studies whether continuous dopaminergic stimulation
(CDS) is a protective factor for dyskinesia [36]. CDS is a
proposedstrategytopreventﬂuctuationsinDAtransmission
and therefore the development of dyskinesia [37]. Studies
with PPX and other DAAs as active comparators show
similar incidence of dyskinesia. In all studies with placebo
comparisons, DAAs have consistently been associated with
more dyskinesia events, suggesting the involvement of
dopaminergic activation. In terms of the pharmacokinetic
proﬁle of PPX (Table 2), its longer half-life compared to
L - D O P Am a k e si td i ﬃcult to explain the higher incidence
of dyskinesias with this treatment. In fact, the shorter
half-life of L-DOPA compared to other antiparkinsonian
medications (such as dopamine D2 receptor agonists) is
regarded as a factor contributing to its pulsatile action and6 Parkinson’s Disease
ultimately to dyskinesia [38]. Moreover, studies on the ER
preparation of PPX, which produces a continuous release
of active ingredient over a twenty-four-hour period [39],
did not ﬁnd high rates of dyskinesia. Finally, there were
no diﬀerences whether the DAA was ergoline (BRC, PGL)
or non-ergoline-based (PPX, RTG). It has therefore been
suggested that previous exposure to L-DOPA (i.e., priming)
can lead to increased susceptibility to develop dyskinesias
after exposure to drugs which would not otherwise have
had this eﬀect. Speciﬁcally, pulsatile activation of type D2
dopamine receptors is reported to be the principal factor in
the triggering of dyskinesias and may well be involved in the
priming phenomenon [40].
Dose-ranging studies of PPX allow some degree of
examination of the hypothesis that PPX-related dyskinesia
may be dosage dependent. One study examining PPX at
doses of 1.5, 3.0, 4.5, and 6.0mg did not report any
incidence of dyskinesia in either treatment or placebo groups
[21]. Another study of diﬀerent schedules of low-dose PPX
(0.5bd, 0.75bd, and 0.5mgtd) also did not report dyskinetic
events in the participants [28]. These ﬁndings suggest that
dyskinesia may not be PPX dose dependent. Exploration of
this hypothesis with other studies is diﬃcult because PPX
dosages are reported as a mean or range of values for the
whole sample. Therefore, it is not possible to determine what
doses were administered to patients with dyskinesia.
Due to insuﬃcient details in published reports, it has
also been diﬃcult to explore whether concomitant APD
usage or patient characteristics (such as illness stage, age,
anddurationofdisease)areassociatedwithdyskinesia.APDs
were either kept constant at baseline dosages or used as add-
ontherapyforemergingdisabilityandthemajorityofstudies
allowed concomitant usage. Furthermore, patient charac-
teristics were reported as mean or range values without
diﬀerentiating which patients exhibited dyskinesia. However,
it is interesting to note that patients with dyskinesias were
generallyolder(earlysixtiesandabove).ThepatientsinPPX-
only studies in which there was no incidence of dyskinesia
were newly diagnosed with PD.
In terms of methodological issues, the duration of the
treatment phase (i.e., titration and maintenance) has overall
been adequate to allow suﬃcient time in detecting or
establishing a timeframe for the onset of dyskinesia. The
samplesizehasalsogenerallybeenstatisticallyviabletoallow
detection of clinically relevant ﬁndings, including dyskinetic
adverse events, although there have been some studies with
smallsamplesizes.Moststudiesalsomaintainedsomeequiv-
alency with patient characteristics in their treatment groups
by carrying out block randomisations and statistical tests
before and after treatment to investigate related diﬀerences
in outcome measures.
More problematic issues, however, may confound con-
clusions about the eﬀects of PPX on dyskinesia. In particular,
some studies only reported adverse events including dyski-
nesia that occurred above threshold incidence, for example,
≥2%, ≥5%, or 10%. Thus, PPX-related dyskinesias may
be underreported and contribute to the lower incidence in
certain studies. Indeed, the studies which did not detect
dyskinesia in their participants had thresholds of reporting
these events at ≥5% [26–28] and 10% [19]. There have
also been studies in which patients already experiencing
motor ﬂuctuations including dyskinesia were enrolled for
PPX treatment. These studies examined whether PPX is a
suitableadjuvantmedicationforL-DOPA-relateddyskinesia.
However,fromthesestudiesitisdiﬃculttoestablishwhether
PPX can contribute to the development of dyskinesias since
it was not described whether the incidence of dyskinesia is
treatment-emergent and relevant neurological scales were
not used to measure eﬀects on these symptoms. The
reporting of dyskinesia in follow-up studies also does not
allow the diﬀerentiation between patients with treatment-
emergent events and those who continued to experience
such symptoms. Additionally, the combination of ratings of
dyskinesia and neurological scales to measure eﬀects of PPX
further confound conclusions without diﬀerentiating which
patients had dyskinetic events. For example, the incidence
of dyskinesia may be high in the PPX group even if the
scales show signiﬁcant improvement associated with PPX
treatment [10, 11, 13].
6. Conclusions
We systematically reviewed the existing evidence on the use
of PPX in PD with focus on the development of dyskinesia.
Treatment with PPX has overall been associated with sig-
niﬁcantly better improvement in motor and daily function
compared to placebo. The majority of placebo-controlled
studies demonstrated that dyskinesias can develop during
PPX treatment, as these symptoms were generally (except for
twostudies)moreprevalentcomparedtotheplacebogroups.
Therefore, the evidence in support of lower incidence of
dyskinesia in combination with PPX is far from convincing.
However, in six studies, no dyskinesia events were reported.
Four of these six studies were PPX comparisons (i.e., dose-
ranging or immediate versus extended release preparation).
Active comparator studies showed that the incidence of
dyskinesia events was quite similar relative to other DAAs.
An L-DOPA comparison study in one cohort with long-
term follow-up consistently showed that PPX treatment was
associated with lower risk for developing dyskinesia. These
symptoms have also been reported in the placebo groups
(albeit at generally lower rates), suggesting the potential
involvement of non-PPX-related factors in the development
of dyskinesia. It is still to be established whether L-DOPA
treatment,PPXdosage,andotherpatientcharacteristicssuch
as age or disease stage can play a role as contributory factors.
Elucidation of such factors is likely to optimise the eﬃcacy of
anti-Parkinson’s treatment and its compliance.
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